Actinogen Medical - Publication of XanADu biomarker analysis
Actinogen Medical announced that the prespecified biomarker subset analyses on stored plasma samples (n=72) from its previous Phase IIa XanADu...
383 Views
Actinogen Medical - Funding in place through key catalysts
Actinogen announced a capital increase of up to A$8.9m on 3 May, consisting of a A$5.0m (gross) placement along with a shareholder rights offering...
171 Views
Actinogen Medical - First patient dosed in Phase IIb XanaMIA study
Actinogen Medical announced that the first randomised patient in its Phase IIb XanaMIA trial of lead candidate Xanamem received their first...
186 Views
Actinogen Medical - Pressing forward with Xanamem
Having shown cognitive activity in prior trials, Actinogen began its XanaMIA Phase IIb study of lead candidate Xanamem in patients with cognitive...
234 Views
Actinogen Medical - Phase IIb XanaMIA study opens first study site
Actinogen Medical has opened the first investigational study site for its Phase IIb XanaMIA trial of lead candidate Xanamem in patients with...
607 Views